IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v17y2016i9d10.1007_s10198-015-0752-3.html
   My bibliography  Save this article

A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure

Author

Listed:
  • F. Tomini

    (Maastricht University Medical Centre
    Cardiovascular Research Institute Maastricht (CARIM))

  • F. Prinzen

    (Cardiovascular Research Institute Maastricht (CARIM))

  • A. D. I. Asselt

    (University of Groningen
    University Medical Centre Groningen)

Abstract

Objectives Cardiac resynchronization therapy with a biventricular pacemaker (CRT-P) is an effective treatment for dyssynchronous heart failure (DHF). Adding an implantable cardioverter defibrillator (CRT-D) may further reduce the risk of sudden cardiac death (SCD). However, if the majority of patients do not require shock therapy, the cost-effectiveness ratio of CRT-D compared to CRT-P may be high. The objective of this study was to systematically review decision models evaluating the cost-effectiveness of CRT-D for patients with DHF, compare the structure and inputs of these models and identify the main factors influencing the ICERs for CRT-D. Methods A comprehensive search strategy of Medline (Ovid), Embase (Ovid) and EconLit identified eight cost-effectiveness models evaluating CRT-D against optimal pharmacological therapy (OPT) and/or CRT-P. Results The selected economic studies differed in terms of model structure, treatment path, time horizons, and sources of efficacy data. CRT-D was found cost-effective when compared to OPT but its cost-effectiveness became questionable when compared to CRT-P. Conclusions Cost-effectiveness of CRT-D may increase depending on improvement of all-cause mortality rates and HF mortality rates in patients who receive CRT-D, costs of the device, and battery life. In particular, future studies need to investigate longer-term mortality rates and identify CRT-P patients that will gain the most, in terms of life expectancy, from being treated with a CRT-D.

Suggested Citation

  • F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
    • Handle: RePEc:spr:eujhec:v:17:y:2016:i:9:d:10.1007_s10198-015-0752-3
    DOI: 10.1007/s10198-015-0752-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-015-0752-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-015-0752-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. J. Kirsch & A. McGuire, 2000. "Establishing health state valuations for disease specific states: an example from heart disease," Health Economics, John Wiley & Sons, Ltd., vol. 9(2), pages 149-158, March.
    2. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
    3. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.
    4. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
    5. George Miller & Stephen Randolph & Emma Forkner & Brad Smith & Autumn Dawn Galbreath, 2009. "Long-Term Cost-Effectiveness of Disease Management in Systolic Heart Failure," Medical Decision Making, , vol. 29(3), pages 325-333, May.
    6. Frank A. Sonnenberg & J. Robert Beck, 1993. "Markov Models in Medical Decision Making," Medical Decision Making, , vol. 13(4), pages 322-338, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    2. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    3. James Shearer & Colin Green & Carl Counsell & John Zajicek, 2011. "The use of decision-analytic models in Parkinson’s disease," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 243-258, July.
    4. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    5. Sun-Young Kim & Sue Goldie, 2008. "Cost-Effectiveness Analyses of Vaccination Programmes," PharmacoEconomics, Springer, vol. 26(3), pages 191-215, March.
    6. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    7. Francesca Pierotti & Ilaria Palla & Maarten Treur & Lara Pippo & Giuseppe Turchetti, 2015. "Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-18, October.
    8. Gordon B. Hazen, 2022. "Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness," INFORMS Journal on Computing, INFORMS, vol. 34(6), pages 3170-3180, November.
    9. Emma McManus & Tracey Sach & Nick Levell, 2018. "The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal," PharmacoEconomics, Springer, vol. 36(1), pages 51-66, January.
    10. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2020. "Modelling the impact of physical activity on public health: A review and critique," Health Policy, Elsevier, vol. 124(10), pages 1155-1164.
    11. Savvas S. Ioannou & Yiola Marcou & Eleni Kakouri & Michael A. Talias, 2020. "Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective," IJERPH, MDPI, vol. 17(12), pages 1-20, June.
    12. David Glynn & Vijay S. Gc & Karl Claxton & Chris Littlewood & Claire Rothery, 2024. "Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation," PharmacoEconomics, Springer, vol. 42(9), pages 919-928, September.
    13. Sarang Deo & Seyed Iravani & Tingting Jiang & Karen Smilowitz & Stephen Samuelson, 2013. "Improving Health Outcomes Through Better Capacity Allocation in a Community-Based Chronic Care Model," Operations Research, INFORMS, vol. 61(6), pages 1277-1294, December.
    14. Christopher H. Jackson & Laura Bojke & Simon G. Thompson & Karl Claxton & Linda D. Sharples, 2011. "A Framework for Addressing Structural Uncertainty in Decision Models," Medical Decision Making, , vol. 31(4), pages 662-674, July.
    15. Gemma E. Shields & Paul Clarkson & Ash Bullement & Warren Stevens & Mark Wilberforce & Tracey Farragher & Arpana Verma & Linda M. Davies, 2024. "Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature," PharmacoEconomics, Springer, vol. 42(7), pages 737-749, July.
    16. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
    17. Ashley Layer & Emma McManus & N. J. Levell, 2020. "A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers," PharmacoEconomics - Open, Springer, vol. 4(2), pages 211-222, June.
    18. Heß, Michael (Ed.) & Schlieter, Hannes (Ed.), 2014. "Modellierung im Gesundheitswesen: Tagungsband des Workshops im Rahmen der Modellierung 2014," ICB Research Reports 57, University Duisburg-Essen, Institute for Computer Science and Business Information Systems (ICB).
    19. Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon, 2018. "Model Structuring for Economic Evaluations of New Health Technologies," PharmacoEconomics, Springer, vol. 36(11), pages 1309-1319, November.
    20. Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies, 2022. "Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency," PharmacoEconomics, Springer, vol. 40(2), pages 149-156, February.

    More about this item

    Keywords

    Review; Cost-effectiveness; Cardiac resynchronization therapy; Cardiac pacing; Implantable cardioverter-defibrillator; Markov chains; Models; Economic; Heart failure; Sudden cardiac death;
    All these keywords.

    JEL classification:

    • C63 - Mathematical and Quantitative Methods - - Mathematical Methods; Programming Models; Mathematical and Simulation Modeling - - - Computational Techniques
    • D61 - Microeconomics - - Welfare Economics - - - Allocative Efficiency; Cost-Benefit Analysis
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • H43 - Public Economics - - Publicly Provided Goods - - - Project Evaluation; Social Discount Rate

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:17:y:2016:i:9:d:10.1007_s10198-015-0752-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.